(Q34740091)

4 August 2017

1 reference

title

Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension (English)

1 reference

4 August 2017

1 reference

Balfour JA

1

1 reference

4 August 2017

Wilde MI

series ordinal

2

1 reference

4 August 2017

publication date

1 May 1997

1 reference

4 August 2017

1 reference

4 August 2017

volume

10

1 reference

4 August 2017

issue

5

1 reference

4 August 2017

page(s)

384-403

1 reference

https://scigraph.springernature.com/pub.10.2165/00002512-199710050-00006

4 August 2017

exact match

0 references

cites work

A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group.

1 reference

12 December 2020

Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey

1 reference

12 December 2020

The relation between enzyme inhibition and physiological response in the carbonic anhydrase system

1 reference

12 December 2020

Adverse reactions from timolol administration

1 reference

12 December 2020

Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor

1 reference

12 December 2020

The development of topical carbonic anhydrase inhibitors

1 reference

12 December 2020

Avoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sympathomimetic agents.

1 reference

12 December 2020

Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide

1 reference

12 December 2020

Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma.

1 reference

12 December 2020

The effect of cyclooxygenase inhibition on the ocular hypotensive action of topical carbonic anhydrase inhibitors in rabbits.

1 reference

12 December 2020

Predicted outcome from hypotensive therapy for glaucomatous optic neuropathy

1 reference

12 December 2020

A comparison of dorzolamide and timolol in patients with pseudoexfoliation and glaucoma or ocular hypertension

1 reference

12 December 2020

Topical dorzolamide-induced hypotony and ciliochoroidal detachment in patients with previous filtration surgery

1 reference

12 December 2020

Dorzolamide, a topical carbonic anhydrase inhibitor: a two-week dose-response study in patients with glaucoma or ocular hypertension.

1 reference

12 December 2020

A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Dorzolamide Dose-Response Study Group.

1 reference

12 December 2020

A comparison of L-671,152 and MK-927, two topically effective ocular hypotensive carbonic anhydrase inhibitors, in experimental animals

1 reference

12 December 2020

Pharmacological advances in the treatment of glaucoma

1 reference

12 December 2020

Patient tolerance to carbonic anhydrase inhibitors

1 reference

12 December 2020

The transcorneal permeability of sulfonamide carbonic anhydrase inhibitors and their effect on aqueous humor secretion

1 reference

12 December 2020

Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor

1 reference

12 December 2020

Determination of MK-507, a novel topically effective carbonic anhydrase inhibitor, and its de-ethylated metabolite in human whole blood, plasma, and urine by high-performance liquid chromatography

1 reference

12 December 2020

Glaucoma: early detection and therapy for prevention of vision loss.

1 reference

12 December 2020

The efficacy of dorzolamide, a topical carbonic anhydrase inhibitor, in combination with timolol in the treatment of patients with open-angle glaucoma and ocular hypertension

1 reference

12 December 2020

1 reference

12 December 2020

Blood dyscrasias and carbonic anhydrase inhibitors

1 reference

12 December 2020

Comparison of quality of life and patient preference of dorzolamide and pilocarpine as adjunctive therapy to timolol in the treatment of glaucoma

1 reference

12 December 2020

Long-term Glaucoma Treatment with MK-507, Dorzolamide, a Topical Carbonic Anhydrase Inhibitor

1 reference

12 December 2020

The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. The Dorzolamide Additivity Study Group

1 reference

12 December 2020

Absorption of ocular timolol

1 reference

12 December 2020

Systemic effects of medications used to treat glaucoma

1 reference

12 December 2020

New developments in the drug treatment of glaucoma

1 reference

12 December 2020

Pseudoexfoliation, intraocular pressure, and senile lens changes in a population-based survey

1 reference

12 December 2020

The pharmacology of antiglaucoma drugs

1 reference

12 December 2020

Blind randomised non-crossover long-term trial comparing topical timolol 0.25% with timolol 0.5% in the treatment of simple chronic glaucoma

1 reference

12 December 2020

MK-507 versus sezolamide. Comparative efficacy of two topically active carbonic anhydrase inhibitors

1 reference

12 December 2020

Chemical properties of carbonic anhydrase IV, the membrane-bound enzyme

1 reference

12 December 2020

Lung-function and glaucoma treatment--a cause for concern?

1 reference

12 December 2020

The ocular hypotensive effect of the topical carbonic anhydrase inhibitor L-671,152 in glaucomatous monkeys

1 reference

12 December 2020

The presentation and prognosis of glaucoma in pseudoexfoliation of the lens capsule

1 reference

12 December 2020

Long-term follow-up of pseudoexfoliation and the development of elevated intraocular pressure

1 reference

12 December 2020

The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor

1 reference

12 December 2020

MK-507 (L-671,152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys

1 reference

12 December 2020

New medical treatments for glaucoma.

1 reference

12 December 2020

Binding of dorzolamide and its metabolite, N-deethylated dorzolamide, to human erythrocytes in vitro

1 reference

12 December 2020

Carbonic anhydrase inhibitor side effects. Serum chemical analysis

1 reference

12 December 2020

Ocular absorption, blood levels, and excretion of dorzolamide, a topically active carbonic anhydrase inhibitor

1 reference

12 December 2020

In vitro metabolism of dorzolamide, a novel potent carbonic anhydrase inhibitor, in rat liver microsomes

1 reference

12 December 2020

Biostatistical evidence for two distinct chronic open angle glaucoma populations

1 reference

12 December 2020

Randomized clinical trials on medical treatment of glaucoma. Are they appropriate to guide clinical practice?

1 reference

12 December 2020

Topical carbonic anhydrase inhibitors: potential adjuvants to glaucoma therapy in the future.

1 reference

12 December 2020

Effect of MK-507 on aqueous humor dynamics in normal human eyes

1 reference

12 December 2020

Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension

1 reference

12 December 2020

10.2165/00002512-199710050-00006

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

1037325055

0 references

1 reference